These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 28742624)

  • 21. Injecting buprenorphine-naloxone film: Findings from an explorative qualitative study.
    White N; Flaherty I; Higgs P; Larance B; Nielsen S; Degenhardt L; Ali R; Lintzeris N
    Drug Alcohol Rev; 2015 Nov; 34(6):623-9. PubMed ID: 26179339
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic switch to buprenorphine/naloxone from buprenorphine alone: clinical experience in an Italian addiction centre.
    Montesano F; Zaccone D; Battaglia E; Genco F; Mellace V
    Clin Drug Investig; 2010; 30 Suppl 1():13-9. PubMed ID: 20450241
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dissatisfaction with opioid maintenance treatment partly explains reported side effects of medications.
    Muller AE; Bjørnestad R; Clausen T
    Drug Alcohol Depend; 2018 Jun; 187():22-28. PubMed ID: 29626742
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Psychiatric Comorbidity and Substance Use Outcomes in an Office-Based Buprenorphine Program Six Months Following Hurricane Sandy.
    Tofighi B; Grossman E; Goldfeld KS; Williams AR; Rotrosen J; Lee JD
    Subst Use Misuse; 2015; 50(12):1571-8. PubMed ID: 26623697
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diversion of opioid maintenance treatment medications and predictors for diversion among Finnish maintenance treatment patients.
    Launonen E; Alho H; Kotovirta E; Wallace I; Simojoki K
    Int J Drug Policy; 2015 Sep; 26(9):875-82. PubMed ID: 25934054
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Urine naloxone concentration at different phases of buprenorphine maintenance treatment.
    Heikman P; Häkkinen M; Gergov M; Ojanperä I
    Drug Test Anal; 2014 Mar; 6(3):220-5. PubMed ID: 23512803
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug test results as a predictor of retention among patients using buprenorphine in a comprehensive outpatient treatment program.
    Campbell MD; Kolodner G; Spencer RA; DuPont RL
    J Addict Dis; 2016; 35(4):315-324. PubMed ID: 26757093
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diversion and injection of buprenorphine-naloxone film two years post-introduction in Australia.
    Larance B; Mattick R; Ali R; Lintzeris N; Jenkinson R; White N; Kihas I; Cassidy R; Degenhardt L
    Drug Alcohol Rev; 2016 Jan; 35(1):83-91. PubMed ID: 26450513
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A retrospective study of retention of opioid-dependent adolescents and young adults in an outpatient buprenorphine/naloxone clinic.
    Matson SC; Hobson G; Abdel-Rasoul M; Bonny AE
    J Addict Med; 2014; 8(3):176-82. PubMed ID: 24695018
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical experience with fortnightly buprenorphine/naloxone versus buprenorphine in Italy: preliminary observational data in an office-based setting.
    Amato P
    Clin Drug Investig; 2010; 30 Suppl 1():33-9. PubMed ID: 20450244
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of 6 remote First Nations community-based buprenorphine programs in northwestern Ontario: Retrospective study.
    Mamakwa S; Kahan M; Kanate D; Kirlew M; Folk D; Cirone S; Rea S; Parsons P; Edwards C; Gordon J; Main F; Kelly L
    Can Fam Physician; 2017 Feb; 63(2):137-145. PubMed ID: 28209683
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prescribing the Buprenorphine Monoproduct for Adverse Effects of Buprenorphine-Naloxone.
    Grande LA
    J Addict Med; 2022 Jan-Feb 01; 16(1):4-6. PubMed ID: 33758111
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial.
    Woody GE; Poole SA; Subramaniam G; Dugosh K; Bogenschutz M; Abbott P; Patkar A; Publicker M; McCain K; Potter JS; Forman R; Vetter V; McNicholas L; Blaine J; Lynch KG; Fudala P
    JAMA; 2008 Nov; 300(17):2003-11. PubMed ID: 18984887
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Injection of medications used in opioid substitution treatment in Australia after the introduction of a mixed partial agonist-antagonist formulation.
    Degenhardt L; Larance BK; Bell JR; Winstock AR; Lintzeris N; Ali RL; Scheuer N; Mattick RP
    Med J Aust; 2009 Aug; 191(3):161-5. PubMed ID: 19645647
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of buprenorphine/naloxone in opioid-dependent patients: an Italian observational study.
    Magnelli F; Biondi L; Calabria R; Fiore A; Peluso E; Vonella D; Rota AG
    Clin Drug Investig; 2010; 30 Suppl 1():21-6. PubMed ID: 20450242
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modeling longitudinal changes in buprenorphine treatment outcome for opioid dependence.
    Saleh MI
    Pharmacopsychiatry; 2014 Nov; 47(7):251-8. PubMed ID: 25321188
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone.
    Fudala PJ; Bridge TP; Herbert S; Williford WO; Chiang CN; Jones K; Collins J; Raisch D; Casadonte P; Goldsmith RJ; Ling W; Malkerneker U; McNicholas L; Renner J; Stine S; Tusel D;
    N Engl J Med; 2003 Sep; 349(10):949-58. PubMed ID: 12954743
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factors associated with non-adherence and misuse of opioid maintenance treatment medications and intoxicating drugs among Finnish maintenance treatment patients.
    Launonen E; Wallace I; Kotovirta E; Alho H; Simojoki K
    Drug Alcohol Depend; 2016 May; 162():227-35. PubMed ID: 27068849
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Injection of buprenorphine and buprenorphine/naloxone tablets in Malaysia.
    Vicknasingam B; Mazlan M; Schottenfeld RS; Chawarski MC
    Drug Alcohol Depend; 2010 Sep; 111(1-2):44-9. PubMed ID: 20478668
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High prevalence of urine tampering in an office-based opioid treatment practice detected by evaluating the norbuprenorphine to buprenorphine ratio.
    Accurso AJ; Lee JD; McNeely J
    J Subst Abuse Treat; 2017 Dec; 83():62-67. PubMed ID: 29129197
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.